The signal hierarchy now spans (a) patient experience (KCCQ) and performance (6MWD) in STEP‐HFpEF, and (b) hard clinical events (HF worsening) plus patient‐reported outcomes in SUMMIT—together informing 2024–2025 scientific statements that place GLP‐1/dual GIP‐GLP‐1 agonists within multidisciplinary obesity management for HFpEF. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.